HIF Prolyl-4-Hydroxylase PHD2 protein abundance depends on integral membrane-anchoring of FKBP38 by Barth, S et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2009
HIF Prolyl-4-Hydroxylase PHD2 protein abundance depends on
integral membrane-anchoring of FKBP38
Barth, S; Edlich, F; Berchner-Pfannschmidt, U; Gneuss, S; Jahreis, G; Hasgall, P A;
Fandrey, J; Wenger, R H; Camenisch, G
Barth, S; Edlich, F; Berchner-Pfannschmidt, U; Gneuss, S; Jahreis, G; Hasgall, P A; Fandrey, J; Wenger, R H;
Camenisch, G (2009). HIF Prolyl-4-Hydroxylase PHD2 protein abundance depends on integral
membrane-anchoring of FKBP38. Journal of Biological Chemistry, 284(34):23046-23058.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Biological Chemistry 2009, 284(34):23046-23058.
Barth, S; Edlich, F; Berchner-Pfannschmidt, U; Gneuss, S; Jahreis, G; Hasgall, P A; Fandrey, J; Wenger, R H;
Camenisch, G (2009). HIF Prolyl-4-Hydroxylase PHD2 protein abundance depends on integral
membrane-anchoring of FKBP38. Journal of Biological Chemistry, 284(34):23046-23058.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Biological Chemistry 2009, 284(34):23046-23058.
Barth et al. 
HIF PROLYL-4-HYDROXYLASE PHD2 PROTEIN ABUNDANCE DEPENDS ON 
INTEGRAL MEMBRANE-ANCHORING OF FKBP38† 
Sandra Barth,1§ Frank Edlich,2‡ Utta Berchner-Pfannschmidt,3 Silke Gneuss,3 Günther Jahreis,2 
Philippe A. Hasgall1, Joachim Fandrey,3 Roland H. Wenger,1 and Gieri Camenisch1* 
 
1Institute of Physiology and Zürich Center for Integrative Human Physiology ZIHP, University of Zürich, 
CH-8057 Zürich, Switzerland; 2Max-Planck Research Unit for Enzymology of Protein Folding, D-06120 
Halle, Germany; 3 Institute of Physiology, University Duisburg-Essen, D-45122 Essen, Germany. 
 
* Corresponding author. Mailing address: Institute of Physiology, University of Zürich, 
Winterthurerstrasse 190, CH-8057 Zürich, Switzerland. Phone: +41 (0)44 63 55075. Fax: +41 (0)44 63 
56814. E-Mail: gieri.camenisch@access.uzh.ch 
 
†Supported by grants from the Forschungskredit der Universität Zürich (to G.C.), the Sassella-Stiftung (to 
G.C. and S.B.), the Hartmann Müller-Stiftung (to G.C.), the Krebsliga des Kanton Zürich (to G.C.), the 
Olga Mayenfisch Stiftung (to G.C.), 6th Framework Programme of the European Commission/SBF grant 
(EUROXY LSHC-CT-2003-502932/SBF Nr. 03.0647-2 to R.H.W.), SNF (3100A0-104219 to R.H.W. 
and G.C.) and the Deutsche Forschungsgemeinschaft (FA 225/19-3 to J.F.). The costs of publication of 
this article were defrayed in part by the payment of page charges. This article must therefore be hereby 
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 
 
Present addresses: §Ben May Department for Cancer Research, University of Chicago, Gordon Center for 
Integrative Sciences, Chicago, Illinois 60637, USA. ‡Biochemistry Section, Surgical Neurology Branch, 
National Institute of Neurological Disorders and Stroke, The National Institutes of Health, Bethesda, 
Maryland 20892, USA. 
 
Running Title: PHD2 protein abundance depends on FKBP38 membrane-anchoring 
 
 1 
Barth et al. 
 2 
Prolyl-4-hydroxylase domain proteins (PHDs) 
are 2-oxoglutarate and dioxygen-dependent 
enzymes that mediate the rapid destruction of 
hypoxia-inducible factor (HIF) α subunits. 
Whereas PHD1 and PHD3 proteolysis has been 
shown to be regulated by Siah2 ubiquitin E3 
ligase-mediated polyubiquitylation and 
proteasomal destruction, protein regulation of 
the main oxygen sensor responsible for HIFα 
regulation, PHD2, remained unknown. We 
recently reported that the FK506-binding 
protein (FKBP) 38 specifically interacts with 
PHD2 and determines PHD2 protein stability in 
a peptidyl prolyl cis/trans isomerase (PPIase)-
independent manner. Using peptide array 
binding assays, fluorescence spectroscopy and 
fluorescence resonance energy transfer (FRET) 
analysis, we define a minimal linear glutamate-
rich PHD2 binding domain in the N-terminal 
part of FKBP38 and show that this domain 
forms a high affinity complex with PHD2. Vice 
versa, PHD2 interacted with a non-linear N-
terminal motif containing the MYND-type Zn2+ 
finger domain with FKBP38. Biochemical 
fractionation and immunofluorescence analysis 
demonstrated that PHD2 subcellular 
localization overlapped with FKBP38 in the 
endoplasmic reticulum (ER) and mitochondria. 
An additional fraction of PHD2 was found in 
the cytoplasm. In cellulo PHD2:FKBP38 
association, as well as regulation of PHD2 
protein abundance by FKBP38, is dependent on 
membrane-anchored FKBP38 localization 
mediated by the C-terminal transmembrane 
domain. Mechanistically, our data indicate that 
PHD2 protein stability is regulated by an 
ubiquitin-independent proteasomal pathway 
involving FKBP38 as adaptor protein that 
mediates proteasomal interaction. We 
hypothesize that FKBP38-bound PHD2 is 
constantly degraded whereas cytosolic PHD2 is 
stable and able to function as active prolyl-4-
hydroxylase.  
 
The heterodimeric α/β transcription factor 
complexes of hypoxia-inducible factors (HIFs) are 
central regulators of the cellular, local and 
systemic response to reduced oxygen partial 
pressure (pO2) (1,2). Under normoxic conditions, 
two highly conserved prolyl residues within the 
oxygen-dependent degradation (ODD) domain of 
HIFα subunits are hydroxylated by members of 
the prolyl-4-hydroxylase domain (PHD) family 
(also called EGLN or HPH) (3-5). Hydroxylated 
prolines are then bound by an E3 ubiquitin ligase 
complex containing the von Hippel-Lindau tumor 
suppressor protein (pVHL) as recognition subunit, 
mediating polyubiquitylation and proteasomal 
degradation of HIFα subunits (6-8). In addition, 
factor inhibiting HIF (FIH) hydroxylates under 
normoxic conditions an asparaginyl residue in the 
C-terminal transcriptional transactivation domain 
of HIFα subunits, preventing the association with 
the CH1 domain of the p300 and CBP co-
activators (9,10). PHDs and FIH belong to the 2-
oxoglutarate- and iron-dependent dioxygenase 
superfamily and act as cellular oxygen sensors by 
correlating the availability of oxygen with the 
regulation of HIF protein stability as well as 
transcriptional activity. Reduced tissue 
oxygenation leads to a concomitant decline in 
PHD and FIH activity, resulting in the 
accumulation of HIFα subunits that translocate to 
the nucleus, heterodimerize with the constitutively 
expressed aryl hydrocarbon receptor nuclear 
translocator (ARNT)/HIFβ subunit and function as 
active transcription factors (11,12).  
Higher metazoans have three PHD genes; 
whereas PHD2 mRNA levels are ubiquitously 
expressed, PHD1 mRNA is present at high levels 
in testes and PHD3 mRNA is most abundant in the 
heart (13). Additionally, a fourth enzyme (P4H) 
has been identified (14). P4H is membrane-
anchored in the endoplasmic reticulum (ER), 
hence more closely related to the collagen prolyl 
hydroxylases, but can also hydroxylate HIFα 
subunits in vitro (15). Using short interfering 
RNAs, PHD2 was shown to be the main regulator 
of normoxic HIFα protein regulation (16). Genetic 
models have supported these findings; whereas 
Phd1-/- and Phd3-/- mice were apparently normal, 
Phd2-/- mice died between embryonic days 12.5 
and 14.5 due to placental and heart defects (17). 
PHD2 was shown to be the main regulator of 
vascular growth (18) as well as renal 
erythropoiesis in adult mice (19), and somatic 
PHD2 inactivation resulted in polycythemia and 
dilated cardiomyopathy (20).  
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Transcript levels of PHD2 and PHD3, but 
not PHD1, are itself regulated by HIF and 
induction under hypoxic conditions leads to 
attenuated HIFα levels (21,22). Initially, it has 
been suggested that this feedback regulation would 
protect from reoxygenation (23,24). We recently 
suggested that induced PHD levels compensate the 
lack of oxygen also under hypoxic conditions and 
thereby define an adapted HIF threshold (25). In 
addition, not only increased PHD levels but also 
overactivation of the catalytic activity of the PHD 
isoforms by chronic hypoxia has been proposed 
(26). The catalytic activity of HIF hydroxylases 
can also be modulated by interfering with the 
different co-factors. Krebs cycle intermediates like 
fumarate and succinate inhibit PHDs and genetic 
defects in fumarate hydratase or succinate 
dehydrogenases predispose to tumor formation 
involving accumulation of HIFα (27-29). In 
addition, also cellular availability of iron and 
ascorbate influences the catalytic activity of HIF 
hydroxylases. Iron and ascorbate supplementation 
suppressed HIF-1α accumulation in cancer cells 
and decreased ascorbate levels resulted in HIF-1α 
stabilization (30,31). Finally, also reactive oxygen 
species (ROS) as well as nitric oxide (NO) have 
been shown to interfere with HIFα stabilization by 
modulating PHD activity (32-34).  
Apart from regulation of PHD mRNA levels 
and hydroxylase activity, differences in PHD 
protein abundance are directly linked to 
hydroxylation activity because HIF hydroxylation 
is a non-reversible process. Strikingly, whereas 
PHD1 and PHD3 protein stability have been 
reported to be regulated by polyubiquitylation 
through the ubiquitin ligase Siah2, probably 
involving additional protein interfaces, the 
proteolytic regulation of the main oxygen sensor 
PHD2 remained unknown (35,36).  
FK506-binding protein 38 (FKBP38) is an 
immunophilin and belongs to the peptidyl prolyl 
cis/trans isomerase protein family (37). 
Ca2+/calmodulin has been shown to bind and 
activate FKBP38, leading to modulation of Bcl-2 
function (38-40). The FKBP38:Bcl-2 interaction 
was blocked by binding of Hsp90 to the 
tetratricopeptide repeat (TPR) domain of FKBP38 
(41,42). In vivo, FKBP38 has been shown to 
control neural tube patterning. Genetic mouse 
models have suggested that FKBP38 functions as 
negative regulator of the sonic hedgehog signaling 
pathway, thereby promoting bone morphogenic 
protein (BMP) signaling (43,44). Recently, we 
reported that FKBP38 interacts with PHD2 and 
regulates PHD2 protein stability (45). While this 
effect was independent of the peptidyl prolyl 
cis/trans isomerase (PPIase) activity of FKBP38, 
the precise molecular mechanism remained 
unknown. Here, we biochemically characterized 
the PHD2:FKBP38 interaction in more detail by 
defining the minimal FKBP38 fragment required 
for PHD2 binding and provide evidence that in 
cellulo interaction as well as functional regulation 
of PHD2 protein abundance depends on the 
membrane-associated localization of FKBP38. 
These findings imply that PHD2 is not diffusely 
distributed in the cytoplasm but localizes to 
defined intracellular structures that determine 
PHD2 protein stability and hydroxylase function.  
 
EXPERIMENTAL PROCEDURES 
 
Plasmids - If not indicated otherwise, cloning was 
carried out using Gateway technology (Invitrogen, 
Basel, Switzerland). Cloning of PCR fragments 
into Entry vectors and recombination to 
Destination vectors was described previously (45). 
All restriction enzymes were purchased from MBI 
Fermentas (Labforce, Nunnigen, Switzerland) or 
New England Biolabs (Bioconcept, Allschwil, 
Switzerland). pENTR4-PHD2 from residues 1 to 
162 (pENTR4-PHD21-162), pENTR4-PHD21-31, 
pENTR4-PHD21-58, pENTR4-PHD21-114 was 
obtained by amplifying the corresponding PHD2 
cDNAs  from the plasmid pENTR/D-PHD2 by 
PCR and cloning into XhoI/NcoI digested 
pENTR4. pENTR/D-PHD221-426 and pENTR/D-
PHD263-426 were obtained by digesting with 
MscI/ScaI or MscI/KasI followed by Klenow fill-
in and re-ligation. pENTR4-FKBP381-389 was 
generated by inserting a stop codon in pENTR4-
FKBP381-412 by site-directed mutagenesis. The 
inserts of all Entry vectors were verified by DNA 
sequencing (Microsynth, Balgach, Switzerland). 
The mammalian Matchmaker vectors pM and 
pVP16 (Clontech, Takara Bio Europe, France) 
were converted to Destination vectors by ligation 
of the Gateway vector conversion cassette reading 
frame B (Invitrogen) into the EcoRI sites of pM 
and pVP16. The mammalian one-hybrid plasmid 
pM-HIF-1α370-429-VP16-AD as well as was GST-
HIF-1α530-826 were generated as described 
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previously (45,46). V5-tagged expression vectors 
were generated by recombination of Entry vectors 
with pcDNA3.1/nV5-DEST. Fluorescent 
expression vectors pECFP-C1 and pEYFP-C1 
(Clontech) were converted to destination vectors 
by ligation of the Gateway vector conversion 
cassette reading frame B (Invitrogen) into the 
SmaI sites of pECFP-C1 and pEYFP-C1 to 
generate pECFP-C1-DEST and pEYFP-C1-DEST, 
respectively.  
Chemicals - Chemicals were purchased from the 
following companies: CHX (Sigma, Buchs, 
Switzerland), E64 (Alexis Biochemicals, Lausen, 
Switzerland), AEBSF (Alexis Biochemicals), 
MG132 (Sigma), ALLM (Calbiochem, Merck 
Chemicals, VWR International, Switzerland), 
Pepstatin A (Alexis Biochemicals). All other 
chemicals were purchased from Sigma.  
Peptide synthesis - Peptides were produced by 
solid-phase peptide synthesis with the robot Syro 
II (MultiSynTech, Witten, Germany) using 0.15 
mmol pre-loaded Fmoc-Asn(Trt)-Wang resin 
(NovaBiochem, Läufelfingen, Switzerland). The 
synthesis was performed by Fmoc strategy and 
standard protocol, as described previously (38). 
The purity of the peptides was evaluated by 
analytical HPLC and the correct molecular masses 
were confirmed by MALDI-TOF mass 
spectrometry. 
Peptide array synthesis - Using the standard SPOT 
synthesis protocol (47), the peptides were 
synthesized stepwise by an Abimed Asp 222 
synthesizer on a cellulose membrane derivatized 
with two β-Ala residues as linker.  
Immunoblot analysis of PHD2 interaction with the 
peptide array - Before immunoblot screening, the 
dry peptide-array membranes were rinsed for 10 
min in methanol and 3 times for 20 min in TBS 
buffer (30 mM Tris/HCl pH 7.6, 170 mM NaCl, 
6.4 mM KCl). PHD2 variant solutions (100 nM) in 
TBS buffer were allowed to react with peptide-
array membranes for 4 hr at 4°C under gentle 
shaking. The membrane was subsequently washed 
3 times with TBS buffer, bound protein blotted 
onto nitrocellulose membranes and analyzed using 
polyclonal rabbit anti-PHD2 antibodies (Novus 
Biologicals, Lubio Science, Lucerne, Switzerland). 
Protein binding assay - Streptavin agarose 
(Sigma) was saturated with Biotin-
EEEEEEEEEEDDLSELPPLE-NH2 peptide and 
washed three times with incubation buffer (25 mM 
Tris/HCl pH 7.5, 200 mM NaCl, 1 mM DTT). 
PHD2 variants (1 μM) were incubated either in 
presence or absence of Ac-
EEEEEEEEEEDDLSELPPLE-NH2 peptide (20 
μM) and FKBP38 (10 μM) with the affinity matrix 
for 1 hr at 4°C. Subsequently, the samples were 
washed three times with incubation buffer and 
subjected to SDS-PAGE. Binding of PHD2 was 
analyzed using polyclonal rabbit anti-PHD2 
antibodies (Novus Biologicals). For incubation 
with endogenous rat proteins, rat liver was 
decomposed in 50 mM Hepes buffer (4% Chaps, 
1% DTT, 100 mM NaCl, 0.1% NaN3, pH 7.5) and 
centrifuged at 14’000 x g for 10 min at 4°C. The 
supernatant was applied to the affinity matrix in 
analogy to the PHD2 proteins. 
Fluorescence spectroscopy - Steady-state 
fluorescence spectra were recorded on a Perkin 
Elmer FluoroMax2 fluorescence spectrometer, 
using a 1 x 1 cm cuvette with an excitation 
wavelength of 280 nm and excitation and emission 
slit widths of 5 and 3 nm, respectively. To 
compensate for inner filter effects, the samples for 
fluorescence measurements were diluted to an 
optical density at 280 nm of 0.15. Protein samples 
were applied in 25 mM Tris/HCl pH 7.5, 200 mM 
NaCl, 1 mM DTT. The binding constant (KD) was 
calculated from the fluorescence intensity by using 
the equation: 
n
K
n
CP D−−
⋅=⋅
)1(
0
0 α
αα  
where P0 = total protein concentration, α = (Fmax - 
F)/(Fmax - F0), Fmax = fluorescence intensity at 
saturation, and F0 = initial fluorescence intensity, n 
= number of independent binding sites, C0 = total 
PHD2 concentration at each addition, and KD = 
dissociation constant. 
Protein expression and purification - GST and 
GST-fusion proteins were expressed in E. coli 
BL21-AI (Invitrogen) by induction with 0.02% 
arabinose for 4 hr and purified using glutathione 
sepharose beads (GE Healthcare, Otelfingen, 
Switzerland). Purification of GST-PHD2 from Sf9 
insect cells was previously described (48). S4 and 
S2 were expressed in E. coli BL21(DE3)pLysS 
from pGEX-6P-PSMC1 and pGEX-6P-PSMD2, 
respectively.  
In vitro transcription/translation (IVTT) and GST 
pull-down - IVTT reactions were carried out as 
described by the manufacturer (Promega, 
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Dübendorf, Switzerland) using recombined 
Destination vectors in the presence of 35S-Met 
(Hartmann Analytic, Braunschweig, Germany). 
Purified GST-tagged proteins (10 μg) were diluted 
in bead binding buffer (50 mM potassium 
phosphate pH 7.5, 150 mM KCl, 1 mM MgCl2, 
10% glycerol, 1% TX-100) and incubated with 
glutathione sepharose beads. For pull-down 
experiments, 20 μl rabbit reticulocyte IVTT 
reactions or 10 μg purified recombinant proteins 
were incubated for 2 hr at 4ºC with bound GST-
fusion proteins in co-IP buffer containing 50 mM 
Tris/HCl pH 7.6, 2 mM EDTA, 100 mM NaCl, 
0.1% TX-100, washed 4 times with co-IP buffer, 
boiled in sample buffer (40 mM Tris/HCl pH 6.8, 
1% SDS, 50 mM β-mercaptoethanol) for 5 min 
and separated by SDS-PAGE. Gels were stained 
with Coomassie blue, dried and radioactively 
labeled proteins detected by phosphorimaging 
(Molecular Imager FX, Bio-Rad, Reinach, 
Switzerland). 
Cell culture and transient transfection - HeLa 
cervical carcinoma, HEK293 embryonic kidney 
carcinoma, MCF-7 breast cancer, mouse ts20 and 
H38-5 cells were cultured in high glucose 
Dulbecco's modified Eagle's medium (DMEM, 
Sigma) as described previously (46). Generation 
of stable RNAi-mediated downregulation of 
FKBP38 was reported previously (45). Briefly, 
HeLa cells were transfected by calcium phosphate 
coprecipitation with pSilencer2.1-U6 hygro 
(Ambion, Huntingdon, United Kingdom), 
containing either a control or FKBP38 targeting 
sequence, and single clones were selected by 
limited dilution. FKBP38 expression was analyzed 
by reverse transcription (RT) quantitative (q) PCR 
and immunoblotting. Strong FKBP38 
downregulation was observed in stable clones 3D6 
and 2G8. Transient transfections were performed 
with the polyethylenimine (PEI; Polysciences, 
Warrington, PA, USA) method as reported before 
(25). 
Immunoblotting - Total cell lysates were prepared 
using RIPA buffer containing 50 mM Tris/HCl pH 
8.0, 1 mM EDTA pH 8.0, 150 mM NaCl, 1% 
Triton X-100, 0.5% Na-deoxycholate, 0.1% SDS. 
Protein concentration was determined using the 
BCA assay (Pierce, Perbio Science, Lausanne, 
Switzerland). Immunoblotting was performed as 
described previously (49). Briefly, protein was 
separated by SDS-PAGE, electro-transferred onto 
nitrocellulose membranes (GE Healthcare) and 
incubated with antibodies. The following 
antibodies were used: rabbit anti-human PHD2 
(Novus Biologicals), rabbit anti-mouse PHD2 
(Novus Biologicals), rabbit anti-FKBP38 (39), 
mouse anti-β-actin (Sigma), mouse anti-PDI 
(Novus Biologicals), rabbit anti-Mitofilin (Novus 
Biologicals), mouse anti-p53 (Santa Cruz 
Biotechnology, Labforce, Nunningen, 
Switzerland), mouse anti-V5 (Invitrogen), mouse 
anti-GST (Sigma), goat anti-S2 (Novus) and rabbit 
anti-S4 antibodies (Novus).  
Bioluminescent assays for proteasomal activity – 
Assays were performed as described by the 
manufacturer (Proteasome-GloTM assay system, 
Promega). Briefly, HeLa cells were lysed in a 
buffer containing 20 mM Tris/HCl pH 7.2, 150 
mM NaCl, 0.1 mM EDTA, 1 mM 2-
mercaptoethanol, 5 mM ATP, 20% glycerol and 
0.1% TX-100. The lysate was centrifuged at 800 x 
g for 5 min at 4°C to pellet the nuclei. The 
supernatant was centrifuged at 100’000 x g for 1 
hr at 4ºC and the resulting supernatant saved as 
cytosolic fraction. The pellet was further lysed in 
the same lysis buffer as described above except 
that TX-100 was 0.5% and centrifuged at 16’000 x 
g for 15 min at 4ºC. The resulting supernatant was 
saved as membrane fraction. Lysates (5 μg in 10 
μl 10 mM Hepes pH 7.6) were incubated at room 
temperature with 10 μl Suc-LLVY-GloTM 
(chymotrypsin-like), Z-LRR-GloTM (trypsin-like) 
or ZnLPnLD-GloTM (caspase-like) reagent for 30 
min before hydrolysis of the peptide was measured 
(Berthold Technologies, Regensdorf, Switzerland).  
Subcellular fractionation - Cells were incubated in 
hypotonic buffer (10 mM HEPES pH 7.5, 1 mM 
EGTA, 25 mM KCl) on ice for 20 min and 
afterwards dounce homogenized in 
homogenization buffer (10 mM HEPES pH 7.5, 1 
mM EDTA, 250 mM sucrose). Cell lysates were 
centrifuged at 3’000 x g for 15 min at 4ºC to pellet 
nuclei and non-lysed cells. To separate the 
membrane from the cytosolic fraction, the 
supernatant was centrifuged at 100’000 x g for 1 
hr at 4ºC. The membrane fraction was resuspended 
in homogenization buffer, overlayed on a 10 to 
30% iodixanol gradient and centrifuged at 150’000 
x g for 18 hr to separate the membrane fractions. 1 
ml fractions were obtained by punctuation of the 
centrifugation tubes and analyzed by 
immunoblotting.  
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Fluorescence microscopy and fluorescence 
resonance energy transfer (FRET) analysis - Cells 
were cultivated on microscope cover slips, washed 
twice with ice-cold PBS, fixed on ice for 30 min 
with 4% paraformaldehyde and permeabilized 
with 0.1% saponine in PBS. Endogenous as well 
as transfected proteins were detected using the 
indicated antibodies. Cellular organelles were 
stained with Mitotracker (Molecular Probes, 
Invitrogen), WGA-Alexa 594 (Molecular Probes, 
Invitrogen) and with antibodies against PDI or 
Calreticulin (Novus Biologicals). Immune 
complexes were visualized with goat anti-rabbit 
Alexa 488, goat anti-mouse Alexa 488, goat anti-
rabbit Alexa 568 or goat anti-mouse Alexa 568 
(Molecular Probes, Invitrogen), respectively. 
Nuclei were stained with DAPI (Sigma) for 30 
min. After extensive washings with PBS, the 
microscope slides were embedded in Mowiol and 
analyzed by confocal laser scanning microscopy 
(SP1, Leica Microsystems, Switzerland). For 
FRET analysis, HEK293 cells were transfected 
with indicated plasmids and FRET was monitored 
as described previously (50). FRET signals were 
analyzed using the sensitized FRET method (51).  
Mammalian one- and two-hybrid assays - 
Mammalian one- and two-hybrid analyses were 
performed using the mammalian Matchmaker 
system (Clontech) as described previously (45). 
HeLa cells were transiently co-transfected with 10 
ng one-hybrid or 1.5 μg Gal4 DNA binding 
domain (DBD) and 1.5 μg Gal4 activation domain 
(AD) fusion protein vectors, together with 500 ng 
firefly luciferase reporter vector pGRE5xE1b and 
20 ng pRL-SV40. Luciferase reporter gene activity 
was determined using the dual luciferase reporter 
assay system according to the manufacturer’s 
instructions (Promega).  
 
RESULTS 
 
Biochemical characterization of the 
PHD2:FKBP38 interaction. Based on our 
previous discovery of the interaction between 
PHD2 and the N-terminal domain of FKBP38, we 
performed a peptide scan to identify the actual 
interaction sites. Thereto, we incubated purified 
recombinant PHD2 with a peptide array of 13-
amino acid (aa) peptides corresponding to the 
sequence of FKBP38, consecutively shifted 
forward by one aa. PHD2 bound to a cluster of 
peptides, which corresponds to the FKBP38 
residues 37 to 56 in the N-terminal extension 
preceding the catalytic domain (Fig. 1A and B 
upper panel). PHD2 did not bind to the inverted 
sequence of this motif in the peptide array, 
demonstrating stereo specificity of the identified 
interaction (Fig. 1B, lower panel). Analogous 
experiments investigating the binding of 
recombinant FKBP38 to a PHD2 peptide array did 
not provide a distinct binding pattern, indicating a 
binding site, which could not be mimicked by the 
13-mer peptides (data not shown).  
Based on these results, the FKBP3837-56 
peptide biotinyl-EEEEEEEEEEDDLSELPPLE-
NH2, which corresponds to the PHD2-interacting 
motif, was immobilized on streptavidin beads and 
analyzed for binding to purified PHD2 protein 
variants. PHD21-426 strongly bound to the affinity 
matrix and binding was significantly diminished in 
the presence of the FKBP3837-56 peptide or 
FKBP38 itself (Fig. 1C), indicating competition 
between the matrix and soluble FKBP38 variants 
for PHD2 binding. In contrast, PHD2170-426 bound 
to the affinity matrix only very weakly, suggesting 
specific binding between the N-terminal PHD2 
domain and FKBP3837-56. Furthermore, 
endogenous rat PHD2 from crude liver lysates 
bound only to the affinity matrix and binding was 
efficiently decreased by addition of the FKBP3837-
56 peptide (Fig. 1D). The identity of bound PHD2 
was confirmed by mass spectrometry analysis 
(data not shown).  
To further analyze the interaction between 
FKBP38 and PHD2, measurements of protein 
fluorescence of both interaction partners were 
performed. The fluorescence spectrum of the 
mixed proteins was blue-shifted by 2 nm and the 
amplitude was increased by 12% compared to the 
calculated sum of the individual protein spectra 
(Fig. 1E). In comparison, no changes in the protein 
fluorescence were observed when PHD2170-426 was 
added to FKBP38 (Suppl. Fig. S1), confirming the 
requirement of the N-terminal PHD2 domain for 
the interaction with FKBP38. The increase in the 
fluorescence signal, which occurs upon 
FKBP38:PHD2 interaction was reduced in the 
presence of the FKBP3837-56 peptide in a 
concentration-dependent manner (Fig. 1F). The 
measurements resulted in a dissociation constant 
(KD) value of 1.48 ± 0.15 µM. Isothermal titration 
calorimetry (ITC) measurements characterized the 
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interaction between PHD2 and the N-terminal 
extension of FKBP38 as a 1:1 complex with a KD 
of 895 ± 148 nM (data not shown). The interaction 
between PHD2 and FKBP3837-56 ITC was 
measured in parallel with a KD of 1.28 ± 0.19 µM, 
which is similar to the result of the fluorescence 
titration curve. 
Mapping the FKBP38 interaction domain in 
PHD2. The PHD2 protein contains a N-terminal 
MYND-type (myeloid, Nervy, and DEAF-1) Zn2+ 
finger domain from residues 21 to 58 and a prolyl-
4-hydroxylase catalytic domain from residues 205 
to 391 (Fig. 2A). We have previously shown that 
the N-terminal region of PHD2 between residues 1 
and 169 interacts with FKBP38 (45). To 
characterize the interaction domain in more detail, 
we generated several PHD2 N-terminal deletion 
constructs and analyzed the interaction by GST 
pull-down experiments. GST-FKBP38 strongly 
interacted with IVTT 35S-labeled full-length PHD2 
and PHD21-162. No interaction was observed with 
any of the N-terminal deletions PHD221-426, 
PHD263-426 and PHD2170-426 (Fig. 2B). GST alone 
did not bind to the different PHD2 fragments. 
Equal input of recombinant proteins was 
confirmed by Coomassie-blue staining (data not 
shown). PHD2 C-terminal deletion fragments were 
purified as GST-fusion proteins from bacteria and 
the in vitro interaction tested with IVTT 35S-
FKBP38 (Fig. 2C and D). FKBP38 only bound to 
GST-PHD21-426 and GST-PHD21-114 but not to 
GST-PHD21-31 and GST-PHD21-58. Taken 
together, these data suggest a non-linear region of 
PHD2, comprising the residues 1 to 20 and 59 to 
114, as interaction domain with FKBP38.  
Ubiquitin-independent proteasomal 
degradation of PHD2. To explore the molecular 
mechanism of FKBP38-mediated PHD2 protein 
regulation, we first sought to investigate the 
proteolytic regulation of PHD2. MCF-7 cells were 
cultivated under normoxic or hypoxic conditions 
and re-oxygenated in the presence of the cysteine 
protease inhibitor E64, the serine protease 
inhibitor AEBSF, the proteasomal inhibitor 
MG132, the calpain and cathepsin inhibitor 
ALLM, the aspartyl protease inhibitor Pepstatin A 
or solvent controls. PHD2 protein levels remained 
unaffected by the various protease inhibitors 
except for MG132, which slightly increased PHD2 
protein levels (data not shown). To further 
investigate the degradation pathway of PHD2, we 
induced PHD2 protein levels by hypoxia and 
analyzed PHD2 protein abundance under 
reoxygenation conditions in the presence or 
absence of MG132 and/or cycloheximide (CHX). 
Overall PHD2 protein abundance as well as PHD2 
protein half-life increased in the presence of 
MG132 (Fig. 3A and B, respectively). Of note, 
addition of hydrogen peroxide from 1 to 250 μM 
altered neither PHD2 nor FKBP38 protein levels 
(data not shown). 
To investigate whether ubiquitylation is 
required for proteolytic PHD2 regulation, we 
made use of mouse ts20 cells that harbor a 
temperature-sensitive E1 ubiquitin-activating 
enzyme (52). Whereas wild-type p53 accumulated 
because of decreased ubiquitin-dependent 
proteasomal degradation when ts20 cells were 
cultivated at restrictive 39°C, PHD2 protein 
abundance was not affected (Fig. 3C). As control, 
incubation of ts20 cells stably transfected with a 
wild-type E1 gene (H38-5) at 34ºC or 39ºC neither 
resulted in p53 nor PHD2 accumulation (Fig. 3D). 
In addition, FKBP38 protein levels were not 
regulated by ubiquitin-mediated proteasomal 
degradation (data not shown). Furthermore, we 
analyzed whether PHD2 protein stability is altered 
under hypoxic conditions. PHD2 protein levels 
were determined in cells treated with CHX and 
cultivated for different time points under normoxic 
or hypoxic conditions. PHD2 protein stability was 
not affected by the differences in pO2 (Suppl. 
Fig.S2).  
 FKBP38 interacts simultaneously with 
proteasomal subunits as well as PHD2 and 
modulates membrane-associated proteasomal 
activity. Nakagawa et al. reported that FKBP38 
interacts with its tetratricopeptide repeat (TPR) 
domains (residues 228 to 339) with subunits of the 
26S proteasome and proposed that anchoring 
proteasomal activity to organellar membranes is 
mediated by FKBP38 (53). To further elaborate 
the mechanism how PHD2 protein stability is 
regulated by FKBP38, we used GST pull-down 
assays and confirmed that FKBP38 interacts with 
the proteasomal subunits S2 and S4 (Fig. 4A and 
B). Furthermore, binding of S2 or S4 to FKBP38 
did not influence simultaneous binding of PHD2 
corroborating that FKBP38 interacts with different 
domains with these proteins. FRET methodology 
was used to analyze whether S4 also interacts in 
cells with FKBP38. FRET signals were detected 
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when CFP-S4 and YFP-FKBP38 were expressed 
in HEK293 cells (Fig.4C). To investigate whether 
cellular proteasomal activity is modulated by 
FKBP38 expression, we measured chymotrypsin-, 
trypsin- and caspase-like activities in parental as 
well as FKBP38-downregulated HeLa cells. 
Whereas cytosolic proteasomal activities were 
increased by FKBP38 suppression, membrane-
associated proteolytic activities were reduced 
compared to parental cells (Fig. 4D). Generation 
and analysis of cells harboring stable RNAi-
mediated downregulation of FKBP38 was reported 
previously (45) (see also Experimental 
Procedures). These data indicate that FKBP38 
anchors the 26S proteasome to intracellular 
membranes and might thereby regulate 
proteasomal PHD2 degradation.  
FKBP38 and PHD2 co-localize in 
mitochondrial and ER fractions. FKBP38 contains 
a C-terminal transmembrane domain (Fig. 1A) and 
has been reported to be an integral ER and 
mitochondrial membrane protein with a topology 
in which the protein is exposed to the cytoplasm 
(39,43). Using indirect immunofluorescence, we 
found co-localization of endogenous FKBP38 with 
ER (calnexin) and mitochondria (Mitotracker) 
marker, but not with the Golgi apparatus (WGA), 
confirming the published results (Suppl. Fig.S3). 
Endogenous PHD2 was found to localize in the 
cytoplasm, mitochondria and to a lesser extent in 
the ER, but not in the Golgi region (Suppl. 
Fig.S3). Next, we analyzed the subcellular 
localization of PHD2 by biochemical fractionation 
in parental (wt) as well as FKBP38 down-
regulated (2G8) HeLa cells cultivated under 
normoxic or hypoxic conditions (Fig. 5). Overall 
PHD2 protein abundance was elevated in 
FKBP38-silenced (Fig. 5B and D) compared to 
parental (Fig. 5A and C) HeLa cells as previously 
reported. FKBP38 protein was present in fractions 
containing mitochondria (mitofilin) as well as ER 
membranes (PDI) as expected. PHD2 was also 
mainly found in mitochondria and ER fractions, 
but also in the high density fraction 10 and in the 
cytosolic fraction (Fig. 5E). In FKBP38-
downregulated cells 2G8, higher PHD2 protein 
levels were observed in ER fractions under 
hypoxic (Fig. 5D) compared to normoxic (Fig. 5B) 
conditions. Taken together, PHD2 co-localized 
with FKBP38 in fractions containing ER and 
mitochondrial membranes and was also found in 
membrane-free cytosolic fractions in which 
FKBP38 was not detectable.  
 FKBP38 membrane-associated localization 
is required for the interaction with PHD2 within 
cells. FRET technology was applied to investigate 
whether membrane insertion of FKBP38 is 
required for PHD2 interaction. Strong FRET 
signals were observed when CFP-FKBP38 and 
YFP-PHD2 were expressed in HEK293 cells but 
not when the PHD2 interaction domain within 
FKBP38 was deleted (CFP-FKBP3899-412, Fig. 
6A). Surprisingly, no FRET signal could be 
recorded when a FKBP38 mutant lacking the 
transmembrane domain (TM) (CFP-FKBP381-389) 
was co-expressed with PHD2, despite the presence 
of the N-terminal interaction domain (Fig. 6A and 
S4). Whereas YFP-labeled FKBP38 and 
FKBP3899-412 co-localized with both of the 
subcellular localization vectors CFP-ER and CFP-
Mito (data not shown) deletion of the TM domain 
of FKBP38 led to a more homogeneous 
distribution throughout the cytoplasm and to some 
nuclear localization (Fig. 6A). However, in in vitro 
GST pull-down experiments FKBP38 interacted 
with PHD2 independently of the FKBP38 TM 
domain (Fig. 6B). To confirm the requirement of 
the FKBP38 TM domain for cellular PHD2 
interaction, we applied mammalian two-hybrid 
technology. The activity of a co-transfected 
luciferase reporter gene construct was greatly 
enhanced when DBD-PHD2 and AD-FKBP381-412 
were co-transfected in HeLa cells, but, consistent 
with the FRET data, no luciferase reporter gene 
activity was measured when the TM domain was 
deleted in FKBP38 (FKBP381-389, Fig. 6C). These 
data suggest that the TM domain of FKBP38 is 
required for the binding to PHD2 in a cellular 
context.  
 FKBP38 transmembrane domain is 
necessary for regulation of PHD2 protein 
abundance. To investigate whether the FKBP38 
TM domain is required for functional regulation of 
PHD2, we transfected cells with full length 
FKBP38, the PPIase domain lacking mutant 
FKBP38Δ98-257 or the TM domain mutant 
FKBP381-389. FKBP38 as well as FKBP38Δ98-257 
localized to the ER and mitochondria as expected, 
whereas deletion of the TM domain in FKBP381-
389 resulted in localization throughout the 
cytoplasm (Suppl. Fig.S4). We previously reported 
that siRNA-mediated FKBP38 down-regulation 
 8 
Barth et al. 
led to increased PHD2 protein levels and reduced 
HIF-1α protein accumulation. On the other hand, 
and in agreement with the previous results, 
expression of full-length FKBP38 and FKBPΔ98-257 
enhanced the activity of a luciferase HIF-1α one-
hybrid reporter construct under normoxic as well 
as hypoxic conditions (Fig. 7A). However, 
FKBP381-389 had no effect on the HIF-1α stability 
reporter and was comparable to the mock 
transfected control (Fig. 7A), indicating that the 
TM domain of FKBP38 is not only required for in 
cellulo interaction, but also for functional PHD2 
regulation. Similar results were obtained in cells 
stably transfected with a control (ctrl) or FKBP38 
siRNA plasmid (3D6, 2G8). Generation of these 
cells was described previously (45). Expression of 
full length FKBP38 increased HIF-1α370-429 one-
hybrid stability, whereas FKBP381-389 had no 
effect (Fig. 7B). Of note that the activity of the 
HIF-1α one-hybrid reporter is decreased in mock 
transfected FKBP38 knock-down cells compared 
to control cells, due to increased PHD2 protein 
abundance. Next, we investigated the effect of 
FKBP38 or FKBP381-389 overexpression on 
endogenous PHD2 protein levels. PHD2 protein 
levels were increased in FKBP38-downregulated 
cells 3D6 and 2G8 compared to control cells and 
PHD2 was attenuated when FKBP38 expression 
was reconstituted (Fig. 7C). Expression of 
FKBP381-389 did not revert elevated PHD2 protein 
levels, confirming that functional PHD2 protein 
regulation requires membrane-associated 
subcellular localization of FKBP38.  
 
DISCUSSION 
 
HIFα protein stability is tightly controlled by O2-
dependent hydroxylation of specific prolyl 
residues within the ODD domain by the HIF 
prolyl-4-hydroxylases. In addition to the 
transcriptional feedback regulation of PHD2 and 
PHD3 by HIF itself, the catalytic activity of the 
PHDs is influenced by numerous factors such as 
Krebs cycle intermediates, availability and 
oxidation state of iron, intracellular ascorbate 
levels, ROS and NO. Whereas the protein stability 
of PHD1 and PHD3 is regulated by 
polyubiquitylation and proteasomal degradation, 
the molecular mechanism of proteolytic PHD2 
regulation remained enigmatic. We recently 
reported that PHD2 protein stability is modulated 
by the peptidyl prolyl cis/trans isomerase FKBP38 
in a PPIase-independent manner. In the present 
study, we biochemically characterized the 
interaction of PHD2 with FKBP38 in more detail, 
provide evidence that PHD2 is degraded in the 
proteasome via an ubiquitin-independent 
mechanism and show that the membrane-
associated subcellular localization of FKBP38 is 
important for functional regulation of PHD2.  
 The motif required for PHD2 binding 
comprised a minimal linear glutamate-rich binding 
domain from the FKBP38 residues 37 to 56 (Fig. 
1). Measurements of the protein fluorescence and 
ITC resulted in a KD value of about 1 μM for the 
interaction between FKBP38 and PHD2, providing 
evidence for a high affinity complex. In addition, 
FRET efficiency for the PHD2:FKBP38 
interaction was very high, indicating a short 
distance between the two molecules and thus close 
interaction (Fig. 6). When compared with FRET 
data recently obtained for the HIF-1α/HIF-1β 
heterodimer, PHD2 and FKBP38 may be closer to 
each other than the subunits of the HIF-1 dimer 
(50). Although so far no data are available to 
correlate distances between proteins within the 
HIF system with function, our data may also 
define the range of protein-protein distances that is 
acceptable for active protein complexes. Larger 
distances may in fact be indicative of additional 
proteins/co-activators contributing to the active 
complex (54).  
FKBP38 interacts with a non-linear motif in 
PHD2 located between residues 1 and 114 (Fig. 2). 
This region contains a MYND-type Zn2+ finger 
domain that has been shown to constitute a 
protein-protein interaction domain implicated in 
transcriptional repression and has been found 
amongst others also in histone methyltransferases 
(55-57). While addition of the Zn2+ chelator 
N,N,N',N'-tetrakis (2-pyridylmethyl) 
ethylenediamine (TPEN) increased the 
hydroxylation activity of full length PHD2, but not 
that of a MYND deletion mutant (58), it did not 
influence the interaction of PHD2 with FKBP38 in 
vitro (data not shown). Previously, the ubiquitin 
E3 ligase Siah2 has been proposed to target PHD1 
and PHD3 for proteasome-dependent degradation, 
whereas PHD2 protein levels remained unchanged 
(35,36). Interestingly, the MYND domain was also 
implicated in proteolytic regulation (59), since N-
 9 
Barth et al. 
terminal MYND domain deletion rendered PHD2 
susceptible to Siah2-mediated polyubiquitylation 
and proteasomal degradation (60). Hence, the 
MYND domain, which is amongst PHDs only 
found in PHD2, might be involved in alternative 
proteolytic regulation of PHD2 compared to PHD1 
and PHD3. Since crystallization of full length 
PHD2 was unsuccessful and a structure was only 
obtained for the catalytic domain of PHD2 (61), 
identification of the PHD2:FKBP38 interaction 
domains might assist computer-based modeling 
and development of small molecules that could 
interfere with the PHD2:FKBP38 interaction, 
resulting in modulated PHD2 protein abundance 
and HIFα stability.  
The mechanism of proteolytic PHD2 
regulation is still unknown. Here, we show that 
inhibition of the proteasomal degradation pathway 
increased PHD2 protein stability, although 
blocking the ubiquitin-activating enzyme E1 did 
not lead to the accumulation of PHD2 (Fig. 3). 
This suggests that polyubiquitylation is not 
required for proteasomal PHD2 degradation. 
Interestingly, a recent approach of measuring 
global protein stability in mammalian cells and 
determination of proteins whose stability was 
changed in response to proteasomal inhibition 
identified PHD2 as proteasome substrate (62). 
Ubiquitin-independent proteasomal degradation 
has been shown for a number of proteins (63) (64) 
(65) (66) (67) (68) and accumulating evidence 
underscores the importance of this pathway in 
addition to classic ubiquitin-dependent 
degradation in the proteasome (69). How 
selectivity of substrate recognition is achieved in 
ubiquitin-independent proteasomal degradation is 
still a matter of debate. Several mechanisms such 
as protein oxidation (70,71) as well as indirect 
substrate recognition through adaptor molecules 
(72) (73) have been proposed. Intriguingly, we 
confirmed data reported by Nakagawa et al. (53) 
and showed that FKBP38 interacts with 
proteasomal subunits in vitro as well as in cellulo 
(Fig. 4). Simultaneous binding of PHD2 and 
proteasomal subunits S2 or S4 to FKBP38 
suggests that FKBP38 might act as adaptor 
protein, mediating proteasomal interaction and 
subsequent degradation of PHD2. Similarly as it 
has been described for Fkbp38-/- mice (53), 
biochemical fractionation revealed reduced 
proteasomal activity in membrane fractions 
derived from FKBP38-downregulated cells (Fig. 
4D), providing an explanation for the increased 
PHD2 protein stability in our FKBP38 knock-
down clones.  
Although the presence of the N-terminal 
PHD2 interaction domain of FKBP38 is sufficient 
to confer in vitro interaction, our data suggest that 
functional regulation of PHD2 protein abundance 
depends on the endogenous, membrane-associated 
subcellular localization of FKBP38 (Fig. 6 and 7). 
Independent reports have indicated that PHD2 can 
localize to different subcellular compartments. 
Initial overexpression data indicated that PHD2 is 
mainly located in the cytoplasm (74,75) and 
analysis of endogenous PHD2 protein localization 
confirmed these data, although also nuclear 
staining was observed in both normal and 
neoplastic tissues (76) as well as various cell lines 
(77). Recently, also mitochondrial and 
peroxisomal  PHD2 localization was reported (78). 
We observed mainly cytoplasmic PHD2 
localization partially overlapping with a 
mitochondrial marker and to a lesser extent also 
with an ER marker (Fig. 5 and Suppl. Fig. S3). 
Although PHD2 and FKBP38 form a high affinity 
complex, PHD2 does not completely co-localize 
with FKBP38 and no shift in subcellular PHD2 
localization was observed in FKBP38-depleted 
cells. Therefore, we hypothesize that a fraction of 
PHD2 binds to FKBP38, which serves as adaptor 
molecule and mediates ubiquitin-independent 
proteasomal degradation, whereas cytosolic PHD2 
is stable and able to function as active prolyl-4-
hydroxylase under optimal enzymatic conditions. 
Clearly, future research is needed to clarify which 
factors regulate the association of PHD2 with 
FKBP38 and how proteasomal recognition of non-
ubiquitylated PHD2 occurs.  
In summary, we biochemically identified 
the interacting regions of PHD2 and FKBP38 and 
provide evidence that PHD2 protein stability is 
regulated by ubiquitin-independent proteasomal 
proteolysis, coherent with the observation that 
membrane-associated subcellular localization of 
FKBP38 is required for functional regulation of 
PHD2 protein levels. Whereas PHD1 and PHD3 
have been shown to undergo Siah2-mediated 
polyubiquitylation and proteasomal degradation, 
this is the first report about the molecular 
mechanism regulating PHD2 protein stability. 
Specific pharmacological disruption of the 
 10 
Barth et al. 
 11 
FKBP38:PHD2 interaction might be a promising 
approach to modulate PHD2 protein abundance 
and HIFα protein stability.  
Barth et al. 
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Malesevic for peptide and peptide array synthesis. The mouse ts20 cells harboring a temperature-sensitive 
E1 ubiquitin-activating enzyme and the reconstituted H38-5 cells were kindly provided by Dr. C. Borner 
(Institute for Molecular Medicine, University of Freiburg, Germany). The plasmids pGEX-6P-PSMC1 
(S4) and pGEX-6P-PSMD2 (S2) were kindly provided by Dr. M. Shirane and Dr. K. I. Nakayama.  
 
The abbreviations used are: aa, amino acids; ARNT, aryl hydrocarbon receptor nuclear translocator; 
EGLN, egg laying defective nine homolog; ER, endoplasmic reticulum; FKBP, FK506-binding protein; 
FRET, fluorescence resonance energy transfer; GST, glutathione S-transferase; HIF, hypoxia-inducible 
factor; HPH, HIF prolyl hydroxylase; IVTT, in vitro transcription/translation; KD, dissociation constant; 
NO, nitric oxide; ODD, oxygen-dependent degradation; PHD, prolyl-4-hydroxylase domain; PPIase, 
peptidyl prolyl cis/trans isomerase; pVHL, von Hippel-Lindau tumor suppressor protein; ROS, reactive 
oxygen species; TPR, tetratricopeptide repeat  
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FIGURE LEGENDS 
 
Fig. 1. Analysis of the PHD2 interaction domain in FKBP38. A. Domain architecture of FKBP381-412. 
PPIase, peptidyl prolyl cis/trans isomerase; TPR, tetratricopeptide repeats; CaM, calmodulin-binding site; 
TM, transmembrane domain. B. An array of 13-mer peptides spanning the FKBP38 sequence was 
synthesized with forward-shifts by one amino acid. PHD2 interaction with the peptide array of the 
FKBP38 sequence forward (upper panel) and reverse (lower panel) was analyzed by immunoblotting. The 
PHD2-interaction pattern is displayed in the frame. The respective binding motif comprised the peptides 
b13-24, which correspond to FKBP3837-56. The reverse sequence comprised of the same residues in the 
reverse order in the peptides f1-12 was not found to interact with PHD2 (lower panel). C. Immunoblot 
analysis of the interaction between two different PHD2 variants and a biotin-labelled FKBP3837-56 peptide 
bound streptavidin matrix using anti-PHD2 antibodies. The streptavidin matrix alone served as control. D. 
Endogenous proteins from rat liver lysates were incubated with a FKBP3837-56 affinity matrix and PHD2 
binding was detected by immunoblotting. The streptavidin matrix alone served as binding control. P 
values were obtained by unpaired t tests (*, P < 0.05; **, P < 0.01). E. Fluorescence measurements at an 
excitation wavelength of 278 nm with 1 μM FKBP38 (___), 1 μM PHD2 (….) and a 1:1 mixture of both 
proteins (----). The calculated spectrum (__ __ __) represents the sum of the individual protein spectra, as it 
should appear when the components do not interact. F. Titration curve resulting from fluorescence 
measurements at 340 nm (excitation at 278 nm) of a sample containing 1 μM FKBP38/PHD2 and various 
concentrations of a peptide corresponding to FKBP3837-56. The straight line represents the fit according to 
the equation in the Materials and Methods section. 
 
 Fig. 2. Mapping the interaction domain of PHD2. A. Schematic representation of the PHD2 domain 
architecture and the used PHD2 constructs. B. IVTT 35S-labeled PHD2 variants were incubated with 
GST-FKBP38 or GST alone. Protein complexes were pulled-down with glutathione sepharose beads, 
separated by SDS-PAGE and visualized by phosphorimaging. C & D. IVTT 35S-labeled FKBP38 was 
incubated with recombinant GST-PHD21-426, GST-PHD2170-426, GST-PHD21-31, GST-PHD21-58, GST-
PHD21-114 or GST alone. Protein complexes were pulled-down and visualized as described above.  
 
 Fig. 3. Proteolytic regulation of PHD2. Cellular extracts were prepared, separated by SDS-PAGE 
and analyzed by immunoblotting. A. MCF-7 cells were pre-incubated for 24 hr at 0.2% O2 and then re-
oxygenated for 20 or 40 hr in the presence of solvent control, MG132 (5 μM) and/or CHX (50 μM). B. 
MCF-7 cells were cultivated for 24 hr under 0.2% O2 before CHX (50 μM) and solvent control or CHX 
and MG132 (5 μM) were added for the indicated time periods. PHD2 and β-actin protein levels were 
analyzed by immunoblotting. C. Mouse ts20 cells were cultivated at either 34ºC or 39ºC for 24, 32 or 48 
hr and cellular extracts were analyzed by immunoblotting. D. Mouse ts20 cells reconstituted with a wild-
type E1 gene (H38-5) were incubated under the same conditions as described in C and cellular proteins 
were analyzed by immunoblotting.  
 
 Fig. 4. FKBP38 regulates proteasomal activity. A & B. Recombinant GST or GST-FKBP38 
proteins were incubated with recombinant S2 or S4 and PHD2 proteins and protein complexes were 
pulled-down with glutathione sepharose beads, separated by SDS-PAGE and visualized by 
immunoblotting. C. HEK293 cells were transiently transfected with CFP-S4 and YFP-FKBP38 plasmids 
and FRET analysis was performed. Subcellular distribution of FRET efficiency signals ranging from 0 % 
to 60 % were visualized in false color mode, as indicated by the color bar (black: 0%, white:60%). FRET 
efficiencies of single cells were averaged and plotted to the acceptor/donor fluorescence ratio. D. 
Cytosolic or membrane fractions of parental or FKBP38-downregulated 2G8 HeLa cells were incubated 
with Suc-LLVY-, Z-LRR- or Z-nLPnLD-aminoluciferin. Results are mean values ± SEM of n=3 
independent experiments performed in triplicates.  
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 Fig. 5. Analysis of FKBP38 and PHD2 protein levels by biochemical fractionation. Parental HeLa 
(wt) or FKBP38-silenced (2G8) HeLa cells were cultivated at 20% O2 (A & B) or at 0.2% O2 (C & D). 
Cellular membranes were separated from cytosolic fractions by differential centrifugation and then 
separated in a 10% to 30% iodixanol gradient. 1 ml fractions were collected and analyzed by 
immunoblotting. Mitofilin served as mitochondria and protein disulfide isomerase (PDI) as ER marker. E. 
Cytosolic fractions of parental HeLa and HeLa 2G8 cells were analyzed by immunoblotting.  
 
 Fig. 6. FKBP38 transmembrane domain is required for PHD2 interaction. A. HEK293 cells were 
transiently transfected with the indicated CFP or YFP plasmids and FRET analysis was performed. B. 
Recombinant GST, GST-FKBP38 or GST-FKBP381-389 proteins were incubated with IVTT 35S-labeled 
PHD2 and protein complexes were pulled-down with glutathione sepharose beads, separated by SDS-
PAGE and visualized by phosphorimaging. C. HeLa cells were transiently transfected with Gal4 DNA-
binding domain (DBD) and Gal4 activation domain (VP16-AD) fusion protein vectors, Gal4 response 
element-driven firefly luciferase reporter as well as a Renilla luciferase control vector. Following 
transfection, the cells were incubated under normoxic (20% O2) or hypoxic (0.2% O2) conditions and 
luciferase reporter gene activities were determined 16 hr later. Firefly to renilla luciferase activity ratios 
were normalized to the normoxic negative control DBD-p53/AD-CP (VP3 polyoma virus coat protein) 
co-transfection which was arbitrarily defined as 1. DBD-p53/AD-LT (large T antigen) served as positive 
control. Mean values ± SEM are shown of n=3 independent experiments performed in triplicates.  
 
 Fig. 7. FKBP38 transmembrane domain is necessary for functional regulation of PHD2. A. MCF-7 
cells were transiently transfected with Gal4-DBD-HIF-1α370-429-VP16-AD expression vector, Gal4 
response element-driven firefly luciferase reporter, a renilla luciferase control vector and either co-
transfected with V5-FKBP38, V5-FKBP38Δ98-357, V5-FKBP381-389 or a mock plasmid (pcDNA3.1-LacZ). 
Twenty-four hr post-transfection, cells were either cultured under normoxic or hypoxic conditions for an 
additional 16 hr, before relative luciferase activities were determined. Results are presented as mean 
values of relative luciferase activities ± SEM of n=4 independent experiments performed in triplicates. P 
values were obtained by paired t tests (** p<0.01; * p<0.05). Expression of the transfected vectors was 
verified by immunoblotting against the V5 tag. B. HeLa FKBP38 RNAi control cells (ctrl) and FKBP38 
RNAi-depleted cells (3D6, 2G8) were transiently transfected with the indicated plasmids as described 
under A. Results are mean values ± SEM of n=7 independent experiments performed in triplicates. C. 
Parental HeLa as well as RNAi control (ctrl) and FKBP38 down-regulated (3D6, 2G8) cells were 
transiently transfected with the indicated plasmids and PHD2, V5 and β-actin were detected by 
immunoblotting.  
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